Granite Investment Partners LLC grew its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 27.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,665 shares of the company’s stock after acquiring an additional 2,985 shares during the quarter. Granite Investment Partners LLC’s holdings in Omnicell were worth $1,105,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of OMCL. Parallel Advisors LLC acquired a new position in shares of Omnicell in the first quarter valued at $28,000. Bronfman E.L. Rothschild L.P. raised its stake in shares of Omnicell by 451.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock valued at $38,000 after purchasing an additional 506 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Omnicell by 125.0% in the first quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after purchasing an additional 300 shares in the last quarter. IFP Advisors Inc raised its stake in Omnicell by 109.3% during the fourth quarter. IFP Advisors Inc now owns 741 shares of the company’s stock worth $45,000 after acquiring an additional 387 shares in the last quarter. Finally, Manchester Capital Management LLC acquired a new position in Omnicell during the first quarter worth $49,000. 97.32% of the stock is owned by institutional investors.
Several research firms have issued reports on OMCL. Zacks Investment Research lowered Omnicell from a “hold” rating to a “sell” rating in a research note on Monday, March 25th. Craig Hallum lowered Omnicell from a “buy” rating to a “hold” rating and set a $84.00 price objective for the company. in a research note on Friday, April 26th. BidaskClub upgraded Omnicell from a “sell” rating to a “hold” rating in a research note on Saturday, May 4th. TheStreet lowered Omnicell from a “b” rating to a “c+” rating in a research note on Thursday, April 25th. Finally, ValuEngine upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Five investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $79.89.
In related news, EVP Nhat H. Ngo sold 1,823 shares of the firm’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $82.33, for a total value of $150,087.59. Following the transaction, the executive vice president now owns 37,569 shares in the company, valued at $3,093,055.77. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Randall A. Lipps sold 65,161 shares of the firm’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $63.77, for a total value of $4,155,316.97. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 131,224 shares of company stock valued at $9,469,511. 2.77% of the stock is currently owned by corporate insiders.
Shares of NASDAQ:OMCL opened at $83.44 on Thursday. Omnicell, Inc. has a twelve month low of $49.45 and a twelve month high of $86.87. The firm has a market capitalization of $3.44 billion, a PE ratio of 54.54, a price-to-earnings-growth ratio of 2.71 and a beta of 1.15. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.96 and a quick ratio of 1.47.
Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, April 25th. The company reported $0.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.23 by $0.38. Omnicell had a return on equity of 11.10% and a net margin of 4.74%. The company had revenue of $202.50 million during the quarter, compared to analyst estimates of $199.72 million. During the same period last year, the company posted $0.29 earnings per share. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. Equities analysts anticipate that Omnicell, Inc. will post 2.06 earnings per share for the current year.
WARNING: This report was first posted by Highlight Press and is owned by of Highlight Press. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://highlightpress.com/2019/06/13/granite-investment-partners-llc-boosts-stake-in-omnicell-inc-nasdaqomcl.html.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.